3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Pancreatic Neoplasms
50
Colorectal Neoplasms
39
Stomach Neoplasms
27
Carcinoma, Hepatocellular
26
Ovarian Neoplasms
25
Melanoma
21
Breast Neoplasms
20
Carcinoma, Non-Small-Cell Lung
19
Neoplasms
15
Neoplasm Metastasis
15
Colonic Neoplasms
14
Esophageal Neoplasms
13
Uterine Cervical Neoplasms
11
Sarcoma
10
Liver Neoplasms
10
Carcinoma, Renal Cell
10
Lung Neoplasms
9
Anus Neoplasms
9
Rectal Neoplasms
8
Head and Neck Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Osteosarcoma
7
Triple Negative Breast Neoplasms
6
Mesothelioma
6
Hepatoblastoma
6
Gastrointestinal Neoplasms
6
Carcinoma
6
Adenocarcinoma
6
Vaginal Neoplasms
5
Small Cell Lung Carcinoma
5
Interventions
Imatinib Mesylate
71
Sunitinib
31
regorafenib
17
nilotinib
15
ripretinib
13
avapritinib
7
Laparoscopy
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
CTLA-4 Antigen
4
Blood Specimen Collection
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Paclitaxel
3
Oxaliplatin
3
Observation
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Biopsy
3
Bevacizumab
3
trametinib
2
tanespimycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
Cyclophosphamide
×
Gastrointestinal
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled